"Amphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
Descriptor ID |
D000661
|
MeSH Number(s) |
D02.092.471.683.152.110
|
Concept/Terms |
Amphetamine- Amphetamine
- Amfetamine
- Phenopromin
- Desoxynorephedrin
- Phenamine
l-Amphetamine- l-Amphetamine
- l Amphetamine
- levo-Amphetamine
- levo Amphetamine
- Levoamphetamine
|
Below are MeSH descriptors whose meaning is more general than "Amphetamine".
Below are MeSH descriptors whose meaning is more specific than "Amphetamine".
This graph shows the total number of publications written about "Amphetamine" by people in this website by year, and whether "Amphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 1 | 2 |
1994 | 1 | 1 | 2 |
1995 | 6 | 1 | 7 |
1996 | 5 | 0 | 5 |
1997 | 3 | 3 | 6 |
1998 | 1 | 0 | 1 |
1999 | 2 | 0 | 2 |
2000 | 1 | 0 | 1 |
2001 | 2 | 0 | 2 |
2002 | 2 | 1 | 3 |
2003 | 1 | 0 | 1 |
2004 | 3 | 0 | 3 |
2005 | 1 | 1 | 2 |
2006 | 2 | 0 | 2 |
2007 | 5 | 0 | 5 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 3 | 0 | 3 |
2011 | 1 | 1 | 2 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amphetamine" by people in Profiles.
-
Mittal S, Boan AD, Kral MC, Lally MD, van Bakergem K, Macias MM, LaRosa A. Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants. J Child Adolesc Psychopharmacol. 2020 03; 30(2):81-86.
-
Connors NJ, Alsakha A, Larocque A, Hoffman RS, Landry T, Gosselin S. Antipsychotics for the treatment of sympathomimetic toxicity: A systematic review. Am J Emerg Med. 2019 10; 37(10):1880-1890.
-
Amato D, Canneva F, Nguyen HP, Bauer P, Riess O, von Hörsten S, Müller CP. Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. J Psychopharmacol. 2017 04; 31(4):461-473.
-
Quina LA, Tempest L, Ng L, Harris JA, Ferguson S, Jhou TC, Turner EE. Efferent pathways of the mouse lateral habenula. J Comp Neurol. 2015 Jan 01; 523(1):32-60.
-
Schwendt M, Sigmon SA, McGinty JF. RGS4 overexpression in the rat dorsal striatum modulates mGluR5- and amphetamine-mediated behavior and signaling. Psychopharmacology (Berl). 2012 Jun; 221(4):621-35.
-
Gipson CD, Beckmann JS, Adams ZW, Marusich JA, Nesland TO, Yates JR, Kelly TH, Bardo MT. A translational behavioral model of mood-based impulsivity: Implications for substance abuse. Drug Alcohol Depend. 2012 Apr 01; 122(1-2):93-9.
-
Shi X, McGinty JF. D1 and D2 dopamine receptors differentially mediate the activation of phosphoproteins in the striatum of amphetamine-sensitized rats. Psychopharmacology (Berl). 2011 Apr; 214(3):653-63.
-
Annamalai B, Mannangatti P, Arapulisamy O, Ramamoorthy S, Jayanthi LD. Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis. J Neurochem. 2010 Oct; 115(1):23-35.
-
Schwendt M, McGinty JF. Amphetamine up-regulates activator of G-protein signaling 1 mRNA and protein levels in rat frontal cortex: the role of dopamine and glucocorticoid receptors. Neuroscience. 2010 Jun 16; 168(1):96-107.
-
Patrick KS, Straughn AB, Perkins JS, González MA. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol. 2009 Jan; 24(1):1-17.